LY3985297
DrugAdministered either IV or SC.
NCT Number: NCT06395012
The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it.
The study is conducted in two parts (part A and B), each part has a separate treatment cohort.
The study will last up to approximately 116 days for part A, and 145 days for part B, including the screening period.
Looking for future studies?
Notify Me18 year–64 year
All sexes
Interventional
Phase 1
CenExel ACT, Anaheim, California, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For Part A Cohorts 5, 6, and 7:
Exclusion criteria
Administered either IV or SC.
Administered either IV or SC.
Time frame: Baseline up to Week 13 (Part A), Week 17 (Part B)
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
Time frame: Predose on day 1 up to Week 13 (Part A), Week 17 (Part B)
Time frame: Predose on day 1 up to Week 13 (Part A), Week 17 (Part B)
Time frame: Predose on day 1 up to Week 13 (Part A), Week 17 (Part B)
Time frame: Predose on day 1 up to Week 13 (Part A), Week 17 (Part B)
Time frame: Predose on day 1 up to Week 13 (Part A), Week 17 (Part B)
Eli Lilly and Company
Industry
A Phase 1, Randomized, Placebo-controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3985297 in Healthy Participants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details